Shares of Wave Life Sciences Ltd. (WVE) are down over 55% from their 52-week high of $56 recorded on September 24, 2018.
Wave Life Sciences is a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases like Duchenne muscular dystrophy, Huntington's disease and inherited retinal diseases.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com